Moderna Inc

MRNA:NASDAQ
RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:59 PM EST
153.95quote price arrow up+2.02 (+1.33%)
Volume
283,641
Close
151.93UNCH (UNCH)
Volume
16,533,666
52 week range
17.91 - 178.50

...

Loading . . .

KEY STATS

  • Open145.15
  • Day High154.55
  • Day Low145.00
  • Prev Close151.93
  • 52 Week High178.50
  • 52 Week High Date12/01/20
  • 52 Week Low17.91
  • 52 Week Low Date02/21/20
  • Market Cap60,120.22M
  • Shares Out395.71M
  • 10 Day Average Volume15.78M
  • Dividend-
  • Dividend Yield-
  • Beta1.74
  • 1 Year % Change619.37

RATIOS/PROFITABILITY

  • EPS (TTM)-1.62
  • P/E (TTM)-93.87
  • Fwd P/E (NTM)18.31
  • EBITDA (MRQ)-584.72M
  • ROE (MRQ)-29.80%
  • Revenue (MRQ)246.71M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-242.27%
  • Debt To Equity (MRQ)3.94%

EVENTS

  • Earnings Date02/24/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

QUOTE FINDER

Related Video

VIDEO6:2406:24
Moderna shares get a boost on latest vaccine news

Profile

MORE
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced...
Noubar Afeyan Ph.D.
Non-Executive Chairman
Stephane Bancel
Chief Executive Officer
Stephen Hoge M.D.
President
David Meline
Chief Financial Officer
Juan Andres
Chief Technology Officer
Lori Henderson J.D.
General Counsel
Address
200 Technology Sq
Cambridge, MA
02139-3578
United States